Entrepreneur File

The Entrepreneur File is a monthly feature in the newsletter that focuses on a start-up company seeking funding.  This feature is not an endorsement of this company. Investors should perform due diligence before investing. 

Tri-Son Medical Inc. 

COMPANY DESCRIPTION:
Health and Medical Services
Medical Devices

COMPANY LOCATION:
1605 Parhams Rd.
Jonesville, LA 71343 

CONTACT:
Steve Johnson
stevendeb@direcway.com

FUNDING: 1. Amount of Current Investment
$35,000

FUNDING: 4. Amount Sought
$350,000

EMPLOYEES: Current full-time, paid

PRODUCT/SERVICE: Description
Tri-Son Medical Inc. is a medical device company that currently owns patent for "SafeRetract", a retractable safety syringe.

PRODUCT/SERVICE: Development Stage
3. Prototype Under Construction

PRODUCT/SERVICE: Patent Status
Patent Received

PRODUCT/SERVICE: Strategy
The SafeRetract syringe fulfills the growing demand for a product which helps reduce the number of accidental needle sticks among healthcare professionals. It is estimated between 600,000 to 800,000 needlestick injuries occur each year. Federal lawmakers recently approved the Needlestick Prevention and Safety Act(HR1578), which requires healthcare facilities to use safety needle products.

MARKETING: Market Niche and Annual Sales Potential
The market segments are clearly defined and growing rapidly. Recent estimates for the "safety needle" market were $100 million US and are expected to grow 40% annually.

MANAGEMENT TEAM and Relevant Experiences
Founder and current CEO is R. Steven Johnson,
a Certified Registered Nurse Anesthetist with 20 years of experience. As developer of SafeRetract, I am aware of its' strengths and the competitive marketplace in which it will compete for market share. I am currently searching for a strong CEO with experience in the field of start-up medical device companies.

FINANCE: 1. Annual Sales, Last Calendar Year

FINANCE: 2. Annual Sales, During this Calendar Year (Projected)

FINANCE: 3. Annual Sales, Next Calendar Year

FINANCE: 4. Annual Sales, Three Year's from Now

OTHER COMMENTS
We are currently in 4th phase of SLA prototyping and preparing for injection mold prototype through Toltec International,Inc. Awaiting capital infusion to continue with FDA application and manufacturing process. Our principal objectives for success after raising initial capitalization are to license the manufacture and sales of the syringe to an aggressive company with similar goals and philosophies as Tri-Son Medical.  We plan to achieve a 2% market penetration in the safety syringe market by the end of the first 12 months of production and achieve 5% market pentration by the end of the 5th year of production which is conservatively projected to be $18-20 million US yearly gross.

back to:   top  articles  home